ELI LILLY & Co is 215.5x more valuable than LIGAND PHARMACEUTICALS INC by market capitalization ($1.072 T vs $4.97 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | LGND | LLY |
|---|---|---|
| Market cap | $4.97 B | $1.072 T |
| US-listed rank | #1389 | #10 |
| Revenue (latest FY) | $268.09M | $65.18B |
| Net income (latest FY) | $124.45M | $20.64B |
| Net margin | 46.4% | 31.7% |
| P/E (trailing FY) | 40.0 | 51.9 |
| SEC filings | 2,226 | 989 |
ELI LILLY & Co is 215.5x more valuable than LIGAND PHARMACEUTICALS INC by market capitalization ($1.072 T vs $4.97 B).
In their latest fiscal years, LIGAND PHARMACEUTICALS INC reported $268.09M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: LIGAND PHARMACEUTICALS INC and ELI LILLY & Co, or browse the full rankings.